159 related articles for article (PubMed ID: 17215857)
21. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
[TBL] [Abstract][Full Text] [Related]
22. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
23. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
24. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
25. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
26. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Okamoto T; Kanamaru A; Shimazaki C; Motoji T; Takemoto Y; Takahashi M; Fukushima T; Takeshita A; Kusumoto GS; Kishimoto Y; Yorimitsu S; Tsukuda K; Uike N; Arima N; Ohno R
Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
[TBL] [Abstract][Full Text] [Related]
28. HLA-DR antigen-negative acute myeloid leukemia.
Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
[TBL] [Abstract][Full Text] [Related]
29. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Bolaños-Meade J; Guo C; Gojo I; Karp JE
Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
[TBL] [Abstract][Full Text] [Related]
31. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
32. [Low-dose chemotherapy].
Ogata K; Yamada T; Dan K
Rinsho Ketsueki; 1996 Sep; 37(9):777-81. PubMed ID: 8914461
[TBL] [Abstract][Full Text] [Related]
33. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Pérez-García A; Brunet S; Berlanga JJ; Tormo M; Nomdedeu J; Guardia R; Ribera JM; Heras I; Llorente A; Hoyos M; Esteve J; Besalduch J; Bueno J; Sierra J; Gallardo D;
Leukemia; 2009 Mar; 23(3):486-91. PubMed ID: 19092854
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Leoni F; Ciolli S; Nozzoli C; Santini V; Fanci R; Rossi Ferrini P
Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
[No Abstract] [Full Text] [Related]
35. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
36. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
38. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
Joventino LP; Stock W; Lane NJ; Daly KM; Mick R; Le Beau MM; Larson RA
Leukemia; 1995 Mar; 9(3):433-9. PubMed ID: 7885042
[TBL] [Abstract][Full Text] [Related]
39. Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Estey EH
Oncology (Williston Park); 1998 Nov; 12(11A):81-6. PubMed ID: 10028504
[TBL] [Abstract][Full Text] [Related]
40. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R; Hellström-Lindberg E; Ohm L; Björkholm M; Celsing F; Dahl IM; Dybedal I; Gahrton G; Lindberg G; Lerner R; Linder O; Löfvenberg E; Nilsson-Ehle H; Paul C; Samuelsson J; Tangen JM; Tidefelt U; Turesson I; Wahlin A; Wallvik J; Winquist I; Oberg G; Bernell P
Leukemia; 2003 Sep; 17(9):1827-33. PubMed ID: 12970783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
